De Novo Synthesis in Cancer Immunotherapy: Applications and Prospects

Abstract

De novo protein design enables the creation of proteins with entirely novel structures and biological functions from scratch, offering a promising new paradigm for cancer immunotherapy. Emerging methodologies are integrating principles of rational design, including specificity, modularity, and adaptability, into the development process from the outset. This innovative strategy holds the potential to advance how people understand and intervene against malignancy, through the strategic utilization of immune checkpoint regulation, cytokine engineering, cellular therapy, and signaling pathway remodeling, with each approach demonstrating distinct mechanisms to augment antitumor immune responses. To further optimize these strategies, advanced computational tools and synthetic biology techniques are now being actively deployed to rationally design immune-modulatory proteins for enhanced cytokine engineering, and to significantly enhance the efficacy of cellular immunotherapies through precision-engineered chimeric antigen receptor T-cell immunotherapy constructs and bispecific antibodies, collectively addressing the key limitations of current therapeutic approaches. To this end, this review discusses how the latest advances in these techniques can deepen our understanding of the usage of de novo-designed proteins in cancer immunotherapy, while also highlighting the key limitations that persist in the field.

Keywords

adoptive cellular therapy / cancer immunotherapy / cytokine engineering / de novo protein design

References

[1] D. M. Pardoll, “The Blockade of Immune Checkpoints in Cancer Immunotherapy,” Nature Reviews Cancer 12, no. 4 (2012): 252–264.

[2] J. R. Hwang, Y. Byeon, D. Kim, and S. G. Park, “Recent Insights of T Cell Receptor-mediated Signaling Pathways for T Cell Activation and Development,” Experimental & Molecular Medicine 52, no. 5 (2020): 750–761.

[3] J. D. Wolchok, V. Chiarion-Sileni, P. Rutkowski, et al., “Final, 10-Year Outcomes With Nivolumab plus Ipilimumab in Advanced Melanoma,” New England Journal of Medicine 392, no. 1 (2025): 11–22.

[4] M. Reck, D. Rodriguez-Abreu, A. G. Robinson, et al., “Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater,” Journal of Clinical Oncology 37, no. 7 (2019): 537–546.

[5] S. J. Antonia, A. Villegas, D. Daniel, et al., “Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer,” New England Journal of Medicine 377, no. 20 (2017): 1919–1929.

[6] S. S. Neelapu, C. A. Jacobson, A. Ghobadi, et al., “Five-year Follow-up of ZUMA-1 Supports the Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-cell Lymphoma,” Blood 141, no. 19 (2023): 2307–2315.

[7] T. A. Waldmann, “The Biology of Interleukin-2 and Interleukin-15: Implications for Cancer Therapy and Vaccine Design,” Nature Reviews Immunology 6, no. 8 (2006): 595–601.

[8] K. Schroder, P. J. Hertzog, T. Ravasi, and D. A. Hume, “Interferon-Gamma: An Overview of Signals, Mechanisms and Functions,” Journal of Leukocyte Biology 75, no. 2 (2004): 163–189.

[9] R. K. Jain, “Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia,” Cancer Cell 26, no. 5 (2014): 605–622.

[10] D. Hanahan and R. A. Weinberg, “Hallmarks of Cancer: The next Generation,” Cell 144, no. 5 (2011): 646–674.

[11] R. Noy and J. W. Pollard, “Tumor-Associated Macrophages: From Mechanisms to Therapy,” Immunity 41, no. 1 (2014): 49–61.

[12] D. I. Gabrilovich and S. Nagaraj, “Myeloid-Derived Suppressor Cells as Regulators of the Immune System,” Nature Reviews Immunology 9, no. 3 (2009): 162–174.

[13] B. E. Correia, Y. E. Ban, D. J. Friend, et al., “Computational Protein Design Using Flexible Backbone Remodeling and Resurfacing: Case Studies in Structure-based Antigen Design,” Journal of Molecular Biology 405, no. 1 (2011): 284–297.

[14] K. K. Yang, Z. Wu, and F. H. Arnold, “Machine-Learning-Guided Directed Evolution for Protein Engineering,” Nature Methods 16, no. 8 (2019): 687–694.

[15] M. Baek, F. DiMaio, I. Anishchenko, et al., “Accurate Prediction of Protein Structures and Interactions Using a Three-Track Neural Network,” Science 373, no. 6557 (2021): 871–876.

[16] P. S. Huang, S. E. Boyken, and D. Baker, “The Coming of Age of De Novo Protein Design,” Nature 537, no. 7620 (2016): 320–327.

[17] N. Koga, R. Tatsumi-Koga, G. Liu, et al., “Principles for Designing Ideal Protein Structures,” Nature 491, no. 7423 (2012): 222–227.

[18] G. S. Murphy, J. B. Greisman, and M. H. Hecht, “De Novo Proteins with Life-Sustaining Functions Are Structurally Dynamic,” Journal of Molecular Biology 428, no. 2 Pt A (2016): 399–411.

[19] C. J. Epstein, R. F. Goldberger, and C. B. Anfinsen, “The Genetic Control of Tertiary Protein Structure: Studies with Model Systems,” Cold Spring Harbor Symposia on Quantitative Biology 28 (1963): 439–449.

[20] P. J. Fleming and G. D. Rose, “Do all Backbone Polar Groups in Proteins Form Hydrogen Bonds?,” Protein Science 14, no. 7 (2005): 1911–1917.

[21] B. Kuhlman, G. Dantas, G. C. Ireton, G. Varani, B. L. Stoddard, and D. Baker, “Design of a Novel Globular Protein Fold With Atomic-level Accuracy,” Science 302, no. 5649 (2003): 1364–1368.

[22] S. E. Boyken, Z. Chen, B. Groves, et al., “De Novo Design of Protein Homo-Oligomers With Modular Hydrogen-Bond Network-Mediated Specificity,” Science 352, no. 6286 (2016): 680–687.

[23] C. Levinthal, “Are there pathways for protein folding?,” Journal de Chimie Physique 65 (1968): 44–45. Posed the famous Levinthal paradox, challenging how proteins fold so efficiently, a cornerstone question in biophysics.

[24] W. F. DeGrado and J. D. Lear, “Induction of Peptide Conformation at Apolar Water Interfaces. 1. A Study With Model Peptides of Defined Hydrophobic Periodicity,” Journal of the American Chemical Society 107, no. 25 (1985): 7684–7689.

[25] B. I. Dahiyat and S. L. Mayo, “De Novo Protein Design: Fully Automated Sequence Selection,” Science 278, no. 5335 (1997): 82–87.

[26] R. F. Alford, A. Leaver-Fay, J. R. Jeliazkov, et al., “The Rosetta all-Atom Energy Function for Macromolecular Modeling and Design,” Journal of Chemical Theory and Computation 13, no. 6 (2017): 3031–3048.

[27] P. S. Huang, G. Oberdorfer, C. Xu, et al., “High Thermodynamic Stability of Parametrically Designed Helical Bundles,” Science 346, no. 6208 (2014): 481–485.

[28] C. B. Anfinsen, “Principles That Govern the Folding of Protein Chains,” Science 181, no. 4096 (1973): 223–230.

[29] J. Lee, Y. Bae, T.-K. Jeong, et al., “De Novo design of a potent Wnt Surrogate Specific for the Frizzled7 Subtype Members,” Preprint, BioRxiv (2025), June 3, 2026, https://doi.org/10.1101/2025.07.28.667009.

[30] J. L. Watson, D. Juergens, N. R. Bennett, et al., “De Novo Design of Protein Structure and Function With RFdiffusion,” Nature 620, no. 7976 (2023): 1089–1100.

[31] H. Stark, F. Faltings, M. Choi, et al., “BoltzGen: Toward Universal Binder Design,” Preprint, BioRxiv (2025), June 3, 2026, https://doi.org/10.1101/2025.11.20.689494.

[32] W. F. Degrado, “Design of Peptides and Proteins,” Advances in Protein Chemistry 39 (1988): 51–124.

[33] I. Samish, C. M. MacDermaid, J. M. Perez-Aguilar, and J. G. Saven, “Theoretical and Computational Protein Design,” Annual Review of Physical Chemistry 62 (2011): 129–149.

[34] P. Mitra, D. Shultis, and Y. Zhang, “EvoDesign: De Novo Protein Design Based on Structural and Evolutionary Profiles,” Nucleic Acids Research 41, no. Web Server issue (2013): W273-80.

[35] J. Dauparas, I. Anishchenko, N. Bennett, et al., “Robust Deep Learning-based Protein Sequence Design Using ProteinMPNN,” Science 378, no. 6615 (2022): 49–56.

[36] J. Jumper, R. Evans, A. Pritzel, et al., “Highly Accurate Protein Structure Prediction With AlphaFold,” Revolutionized structural biology by predicting protein structures with experimental accuracy using AI, Nature 596, no. 7873 (2021): 583–589.

[37] A. Vaswani, N. Shazeer, and N. Parmar, “Attention Is All You Need,” in Advances in Neural Information Processing Systems (2017).

[38] Z. Lin, H. Akin, R. Rao, et al., “Evolutionary-Scale Prediction of Atomic-Level Protein Structure With a Language Model,” Science 379, no. 6637 (2023): 1123–1130.

[39] A. W. Senior, R. Evans, J. Jumper, et al., “Improved Protein Structure Prediction Using Potentials From Deep Learning,” Nature 577, no. 7792 (2020): 706–710.

[40] A. W. Senior, R. Evans, J. Jumper, et al., “Protein Structure Prediction Using Multiple Deep Neural Networks in the 13th Critical Assessment of Protein Structure Prediction (CASP13),” Proteins 87, no. 12 (2019): 1141–1148.

[41] W. Humphrey, A. Dalke, and K. Schulten, “VMD: Visual Molecular Dynamics,” Journal of Molecular Graphics 14, no. 1 (1996): 33–38.

[42] M. J. Abraham, T. Murtola, R. Schulz, et al., “GROMACS: High Performance Molecular Simulations Through Multi-Level Parallelism From Laptops to Supercomputers,” SoftwareX 1-2 (2015): 19–25.

[43] M. C. R. Melo, R. C. Bernardi, T. Rudack, et al., “NAMD Goes Quantum: An Integrative Suite for Hybrid Simulations,” Nature Methods 15, no. 5 (2018): 351–354.

[44] Y. Cheng, “Single-particle Cryo-EM-How Did It Get Here and Where Will It Go,” Science 361, no. 6405 (2018): 876–880.

[45] N. J. Greenfield, “Using Circular Dichroism Spectra to Estimate Protein Secondary Structure,” Nature Protocols 1, no. 6 (2006): 2876–2890.

[46] R. Perozzo, G. Folkers, and L. Scapozza, “Thermodynamics of Protein-Ligand Interactions: History, Presence, and Future Aspects,” Journal of Receptor and Signal Transduction Research 24, no. 1-2 (2004): 1–52.

[47] L. Damian, “Isothermal Titration Calorimetry for Studying Protein-Ligand Interactions,” Methods in Molecular Biology 1008 (2013): 103–118.

[48] D. A. Silva, S. Yu, U. Y. Ulge, et al., “De Novo Design of Potent and Selective Mimics of IL-2 and IL-15,” Nature 565, no. 7738 (2019): 186–191. This landmark study validated computational de novo design for creating cytokine mimetics with enhanced therapeutic properties, revolutionizing immunomodulatory protein engineering.

[49] C. Mortales, B. Dutzar, J. Chen, et al., “NL-201 Upregulates MHC-I Expression and Intratumoral T-cell Receptor Diversity, and Demonstrates Robust Antitumor Activity as Monotherapy and in Combination With PD-1 Blockade,” Cancer Immunology Research 11, no. 7 (2023): 1000–1010.

[50] J. H. Chun, B. S. Lim, S. Roy, et al., “Design of a Potent Interleukin-21 Mimic for Cancer Immunotherapy,” Science Immunology 10, no. 111 (2025): eadx1582.

[51] M. Exposit, M. Abedi, A. Krishnakumar, et al., “Geometric Tuning of Cytokine Receptor Association Modulates Synthetic Agonist Signaling,” Preprint, BioRxiv (2025), June 3, 2026, https://doi.org/10.1101/2025.10.12.681819.

[52] B. Huang, B. Coventry, M. T. Borowska, et al., “De Novo Design of Miniprotein Antagonists of Cytokine Storm Inducers,” Nature Communications 15, no. 1 (2024): 7064.

[53] S. Berger, F. Seeger, T. Y. Yu, et al., “Preclinical Proof of Principle for Orally Delivered Th17 Antagonist Miniproteins,” Cell 187, no. 16 (2024): 4305–4317.

[54] H. Qin, J. P. Edwards, L. Zaritskaya, et al., “Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-Specific Antitumor Activity of T Cells,” Molecular Therapy 27, no. 7 (2019): 1262–1274.

[55] J. M. Buonato, J. P. Edwards, L. Zaritskaya, et al., “Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain,” Molecular Cancer Therapeutics 21, no. 7 (2022): 1171–1183.

[56] M. R. Bishop, J. Rosenblatt, B. Dhakal, et al., “Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety With 34-Month Median Follow-up,” Blood 144, no. Supplement 1 (2024): 4825–4825.

[57] K. Patel, B. Dhakal, G. Kaur, et al., “Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Updated Results From iMMagine–1,” Blood 146, no. Supplement 1 (2025): 256–256.

[58] K. H. Johansen, D. S. Wolff, B. Scapolo, et al., “De Novo-Designed pMHC Binders Facilitate T Cell-Mediated Cytotoxicity Toward Cancer Cells,” Science 389, no. 6758 (2025): 380–385.

[59] M. Mergen, D. Abele, N. Koleci, et al., “Engineering De Novo Binder CAR-T Cell Therapies With Generative AI,” Preprint, BioRxiv (2024), June 3, 2026, https://doi.org/10.1101/2024.11.25.625151.

[60] M. J. Lajoie, S. E. Boyken, A. I. Salter, et al., “Designed Protein Logic to Target Cells With Precise Combinations of Surface Antigens,” Science 369, no. 6511 (2020): 1637–1643.

[61] Z. Chen, R. D. Kibler, A. Hunt, et al., “De Novo Design of Protein Logic Gates,” Science 368, no. 6486 (2020): 78–84.

[62] N. I. Edman, A. Phal, R. L. Redler, et al., “Modulation of FGF Pathway Signaling and Vascular Differentiation Using Designed Oligomeric Assemblies,” Cell 187, no. 14 (2024): 3726–3740.

[63] S. Buckley, Y. Miao, M. Idris, et al., “De Novo Design of Phosphorylation-Induced Protein Switches for Synthetic Signaling in Cells,” Preprint, BioRxiv (2025), June 3, 2026, https://doi.org/10.1101/2025.09.10.675034.

[64] M. Escobar-Rosales, C. Montaner, M. Exposit, et al., “De Novo Design of Peptide Masks Enables Rapid Generation of Conditionally-Active Miniprotein Binders,” Journal of the American Chemical Society 147, no. 49 (2025): 45495–45505.

[65] A. Roy, L. Shi, A. Chang, et al., “De Novo Design of Highly Selective Miniprotein Inhibitors of Integrins alphavbeta6 and alphavbeta8,” Nature Communications 14, no. 1 (2023): 5660.

[66] W. Yang, D. R. Hicks, A. Ghosh, et al., “Design of High-affinity Binders to Immune Modulating Receptors for Cancer Immunotherapy,” Nature Communications 16, no. 1 (2025): 2001.

[67] L. Zhao, F. Zhang, R. Yao, et al., “De Novo Design of Ultrahigh-Affinity Miniproteins Targeting PD-L1 for Non-Invasive Imaging: Preclinical Validation and First-in-Human Study,” medRxiv (2025), 2025.08.08.25333138.

[68] H. Zhou, B. Hou, Y. Shan, et al., “De Novo Design of Structure-Tunable Multivalent Targeting Chimeras for Tumor-Targeted PD-L1 Degradation and Potentiated Cancer Immunotherapy,” Angewandte Chemie 64, no. 27 (2025): e202504233.

[69] W. J. Leonard and J. X. Lin, “Strategies to Therapeutically Modulate Cytokine Action,” Nature Reviews Drug Discovery 22, no. 10 (2023): 827–854.

[70] D. J. Propper and F. R. Balkwill, “Harnessing Cytokines and Chemokines for Cancer Therapy,” Nature Reviews Clinical Oncology 19, no. 4 (2022): 237–253.

[71] T. C. Wu, K. Xu, J. Martinek, et al., “IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients With Metastatic Breast Cancer,” Cancer Research 78, no. 18 (2018): 5243–5258.

[72] W. Li, Z. Wu, W. Meng, et al., “Blockade of IL-6 Inhibits Tumor Immune Evasion and Improves anti-PD-1 Immunotherapy,” Cytokine 158 (2022): 155976.

[73] M. Desbois, C. Beal, M. Charrier, et al., “IL-15 Superagonist RLI Has Potent Immunostimulatory Properties on NK Cells: Implications for Antimetastatic Treatment,” Journal for ImmunoTherapy of Cancer 8, no. 1 (2020).

[74] K. Ozaki and W. J. Leonard, “Cytokine and Cytokine Receptor Pleiotropy and Redundancy,” Journal of Biological Chemistry 277, no. 33 (2002): 29355–29358.

[75] P. Berraondo, M. F. Sanmamed, M. C. Ochoa, et al., “Cytokines in Clinical Cancer Immunotherapy,” British Journal of Cancer 120, no. 1 (2019): 6–15.

[76] S. A. Rosenberg, M. T. Lotze, L. M. Muul, et al., “A Progress Report on the Treatment of 157 Patients With Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone,” New England Journal of Medicine 316, no. 15 (1987): 889–897.

[77] R. Hernandez, J. Poder, K. M. LaPorte, and T. R. Malek, “Engineering IL-2 for Immunotherapy of Autoimmunity and Cancer,” Nature Reviews Immunology 22, no. 10 (2022): 614–628.

[78] P. G. Holder, S. A. Lim, C. S. Huang, et al., “Engineering Interferons and Interleukins for Cancer Immunotherapy,” Advanced Drug Delivery Reviews 182 (2022): 114112.

[79] J. P. Siegel and R. K. Puri, “Interleukin-2 Toxicity,” Journal of Clinical Oncology 9, no. 4 (1991): 694–704.

[80] J. Ren, A. E. Chu, K. M. Jude, et al., “Interleukin-2 Superkines by Computational Design,” PNAS 119, no. 12 (2022): e2117401119.

[81] A. M. Levin, D. L. Bates, A. M. Ring, et al., “Exploiting a Natural Conformational Switch to Engineer an Interleukin-2 ‘Superkine’,” Nature 484, no. 7395 (2012): 529–533.

[82] A. Quijano-Rubio, U. Y. Ulge, C. D. Walkey, and D. A. Silva, “The Advent of De Novo Proteins for Cancer Immunotherapy,” Current Opinion in Chemical Biology 56 (2020): 119–128.

[83] A. Quijano-Rubio, A. M. Bhuiyan, H. Yang, et al., “A Split, Conditionally Active Mimetic of IL-2 Reduces the Toxicity of Systemic Cytokine Therapy,” Nature Biotechnology 41, no. 4 (2023): 532–540.

[84] T. A. Wynn, “Type 2 Cytokines: Mechanisms and Therapeutic Strategies,” Nature Reviews Immunology 15, no. 5 (2015): 271–282.

[85] N. E. Nieuwenhuizen, F. Kirstein, J. Jayakumar, et al., “Allergic Airway Disease Is Unaffected by the Absence of IL-4Ralpha-Dependent Alternatively Activated Macrophages,” Journal of Allergy and Clinical Immunology 130, no. 3 (2012): 743–750.

[86] X. Wang, P. Lupardus, S. L. Laporte, and K. C. Garcia, “Structural Biology of Shared Cytokine Receptors,” Annual Review of Immunology 27 (2009): 29–60.

[87] I. S. Junttila, R. J. Creusot, I. Moraga, et al., “Redirecting Cell-type Specific Cytokine Responses With Engineered Interleukin-4 Superkines,” Nature Chemical Biology 8, no. 12 (2012): 990–998.

[88] S. L. LaPorte, Z. S. Juo, J. Vaclavikova, et al., “Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 System,” Cell 132, no. 2 (2008): 259–272.

[89] H. Yang, U. Y. Ulge, A. Quijano-Rubio, et al., “Design of Cell-type-specific Hyperstable IL-4 Mimetics via Modular De Novo Scaffolds,” Nature Chemical Biology 19, no. 9 (2023): 1127–1137.

[90] G. C. Sim and L. Radvanyi, “The IL-2 Cytokine family in Cancer Immunotherapy,” Cytokine & Growth Factor Reviews 25, no. 4 (2014): 377–390.

[91] M. Abedi, M. Exposit, B. Coventry, et al., “High-Throughput De Novo Protein Design Yields Novel Immunomodulatory Agonists,” Preprint, BioRxiv (2025), June 3 2026, https://doi.org/10.1101/2025.10.12.681920.

[92] J. B. Moore and C. H. June, “Cytokine Release Syndrome in Severe COVID-19,” Science 368, no. 6490 (2020): 473–474.

[93] R. Karki and T. D. Kanneganti, “The ‘Cytokine Storm’: Molecular Mechanisms and Therapeutic Prospects,” Trends in Immunology 42, no. 8 (2021): 681–705.

[94] S. L. Gaffen, R. Jain, A. V. Garg, and D. J. Cua, “The IL-23-IL-17 Immune Axis: From Mechanisms to Therapeutic Testing,” Nature Reviews Immunology 14, no. 9 (2014): 585–600.

[95] A. J. Brooks, W. Dai, M. L. O'Mara, et al., “Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor,” Science 344, no. 6185 (2014): 1249783.

[96] B. A. Witthuhn, F. W. Quelle, O. Silvennoinen, et al., “JAK2 associates With the Erythropoietin Receptor and Is Tyrosine Phosphorylated and Activated Following Stimulation With Erythropoietin,” Cell 74, no. 2 (1993): 227–236.

[97] M. Mravic, L. He, H. T. Kratochvil, et al., “De Novo-Designed Transmembrane Proteins Bind and Regulate a Cytokine Receptor,” Nature Chemical Biology 20, no. 6 (2024): 751–760.

[98] K. Maksymenko, V. Hatskovska, M. Coles, et al., “A Complementarity-Based Approach to De Novo Binder Design,” Adv Sci (Weinh) 12, no. 33 (2025): e02015.

[99] M. Sadelain, I. Riviere, and S. Riddell, “Therapeutic T Cell Engineering,” Nature 545, no. 7655 (2017): 423–431.

[100] H. Shi, M. Sun, L. Liu, and Z. Wang, “Chimeric Antigen Receptor for Adoptive Immunotherapy of Cancer: Latest Research and Future Prospects,” Molecular Cancer 13 (2014): 219.

[101] S. L. Maude, N. Frey, P. A. Shaw, et al., “Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia,” New England Journal of Medicine 371, no. 16 (2014): 1507–1517.

[102] C. H. June and M. Sadelain, “Chimeric Antigen Receptor Therapy,” New England Journal of Medicine 379, no. 1 (2018): 64–73.

[103] J. H. Park, I. Riviere, M. Gonen, et al., “Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia,” New England Journal of Medicine 378, no. 5 (2018): 449–459.

[104] A. H. Long, W. M. Haso, J. F. Shern, et al., “4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors,” Nature Medicine 21, no. 6 (2015): 581–590.

[105] R. G. Majzner, S. P. Rietberg, L. Labanieh, et al., “Low CD19 Antigen Density Diminishes Efficacy of CD19 CAR T Cells and Can be Overcome by Rational Redesign of CAR Signaling Domains,” Blood 132 (2018): 963.

[106] A. J. Walker, R. G. Majzner, L. Zhang, et al., “Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase,” Molecular Therapy 25, no. 9 (2017): 2189–2201.

[107] R. C. Sterner and R. M. Sterner, “CAR-T Cell Therapy: Current Limitations and Potential Strategies,” Blood Cancer Journal 11, no. 4 (2021): 69.

[108] R. A. Morgan, J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. A. Rosenberg, “Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2,” Molecular Therapy 18, no. 4 (2010): 843–851.

[109] M. Hudecek, D. Sommermeyer, P. L. Kosasih, et al., “The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for in Vivo Antitumor Activity,” Cancer Immunology Research 3, no. 2 (2015): 125–135.

[110] A. Schmidts and M. V. Maus, “Making CAR T Cells a Solid Option for Solid Tumors,” Frontiers in Immunology 9 (2018): 2593.

[111] R. G. Majzner and C. L. Mackall, “Tumor Antigen Escape From CAR T-Cell Therapy,” Cancer Discovery 8, no. 10 (2018): 1219–1226.

[112] A. Chow, H. Chu, R. Li, et al., “Sequence and Structural Determinants of Efficacious De Novo Chimeric Antigen Receptors,” Preprint, BioRxiv (2025), June 3, 2026, https://doi.org/10.64898/2025.12.12.694033.

[113] S. T. Walsh, H. Cheng, J. W. Bryson, H. Roder, and W. F. DeGrado, “Solution Structure and Dynamics of a De Novo Designed Three-Helix Bundle Protein,” PNAS 96, no. 10 (1999): 5486–5491.

[114] K. C. Garcia, M. Degano, R. L. Stanfield, et al., “An Αβ T Cell Receptor Structure at 2.5 Å and Its Orientation in the TCR-MHC Complex,” Science 274, no. 5285 (1996): 209–219.

[115] M. M. Davis and P. J. Bjorkman, “T-Cell Antigen Receptor Genes and T-Cell Recognition,” Nature 334, no. 6181 (1988): 395–402.

[116] S. A. Rosenberg and N. P. Restifo, “Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer,” Science 348, no. 6230 (2015): 62–68.

[117] P. F. Robbins, R. A. Morgan, S. A. Feldman, et al., “Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1,” Journal of Clinical Oncology 29, no. 7 (2011): 917–924.

[118] B. Liu, N. F. Greenwood, J. E. Bonzanini, et al., “Design of High-specificity Binders for Peptide-MHC-I Complexes,” Science 389, no. 6758 (2025): 386–391.

[119] K. D. Householder, X. Xiang, K. M. Jude, et al., “De Novo Design and Structure of a Peptide-centric TCR Mimic Binding Module,” Science 389, no. 6758 (2025): 375–379.

[120] J. Luo, M. Guo, M. Huang, et al., “Neoleukin-2/15-armored CAR-NK Cells Sustain Superior Therapeutic Efficacy in Solid Tumors via c-Myc/NRF1 Activation,” Signal Transduction Target Therapy 10, no. 1 (2025): 78.

[121] E. Dantoing, N. Piton, M. Salaun, L. Thiberville, and F. Guisier, “Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer With Actionable Oncogenic Driver Mutations,” International Journal of Molecular Sciences 22, no. 12 (2021).

[122] W. A. Lim and C. H. June, “The Principles of Engineering Immune Cells to Treat Cancer,” Cell 168, no. 4 (2017): 724–740.

[123] L. Morsut, K. T. Roybal, X. Xiong, et al., “Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors,” Cell 164, no. 4 (2016): 780–791.

[124] S. Toda, L. R. Blauch, S. K. Y. Tang, L. Morsut, and W. A. Lim, “Programming Self-organizing Multicellular Structures With Synthetic Cell-cell Signaling,” Science 361, no. 6398 (2018): 156–162.

[125] G. You, J. Choi, C. Yang, et al., “Expanding the Horizons of Cancer Therapy With Next-Generation 4-1BB Agonists: A Review of Molecular and Clinical Strategies to Maximize Efficacy and Ensure Safety,” MAbs 18, no. 1 (2026): 2622746.

[126] L. Cao, B. Coventry, I. Goreshnik, et al., “Design of Protein-binding Proteins From the Target Structure Alone,” Nature 605, no. 7910 (2022): 551–560.

[127] N. Turner and R. Grose, “Fibroblast Growth Factor Signalling: From Development to Cancer,” Nature Reviews Cancer 10, no. 2 (2010): 116–129.

[128] S. J. Bray and A. Bigas, “Modes of Notch Signalling in Development and Disease,” Nature Reviews Molecular Cell Biology 26, no. 7 (2025): 522–537.

[129] A. Nianias and M. Themeli, “Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges,” Current Hematology Malignancy Reports 14, no. 4 (2019): 261–268.

[130] R. Mout, R. Jing, M. Tanaka-Yano, et al., “Design of Soluble Notch Agonists That Drive T Cell Development and Boost Immunity,” Cell 188, no. 21 (2025): 5980–5994.

[131] M. H. Hatada, X. Lu, E. R. Laird, et al., “Molecular Basis for Interaction of the Protein Tyrosine Kinase ZAP-70 With the T-Cell Receptor,” Nature 377, no. 6544 (1995): 32–38.

[132] N. B. Woodall, Z. Weinberg, J. Park, et al., “De Novo Design of Tyrosine and Serine Kinase-Driven Protein Switches,” Nature Structural & Molecular Biology 28, no. 9 (2021): 762–770.

[133] G. Ahn, B. Coventry, E. Haefner, et al., “Computational Design of pH-Sensitive Binders,” Preprint, BioRxiv (2025), June 3, 2026, https://doi.org/10.1101/2025.09.29.678932.

[134] B. Wu, B. Zhang, B. Li, H. Wu, and M. Jiang, “Cold and Hot Tumors: From Molecular Mechanisms to Targeted Therapy,” Signal Transduction Target Therapy 9, no. 1 (2024): 274.

[135] H. Y. Liu, X. J. Sun, S. Y. Xiu, et al., “Frizzled Receptors (FZDs) in Wnt Signaling: Potential Therapeutic Targets for Human Cancers,” Acta Pharmacologica Sinica 45, no. 8 (2024): 1556–1570.

[136] R. O. Hynes, “Integrins: Bidirectional, Allosteric Signaling Machines,” Cell 110, no. 6 (2002): 673–687.

[137] K. Ley, C. Laudanna, M. I. Cybulsky, and S. Nourshargh, “Getting to the Site of Inflammation: The Leukocyte Adhesion Cascade Updated,” Nature Reviews Immunology 7, no. 9 (2007): 678–689.

[138] T. Schurpf and T. A. Springer, “Regulation of Integrin Affinity on Cell Surfaces,” Embo Journal 30, no. 23 (2011): 4712–4727.

[139] T. A. Springer, “Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm,” Cell 76, no. 2 (1994): 301–314.

[140] C. G. Gahmberg, S. C. Fagerholm, S. M. Nurmi, T. Chavakis, S. Marchesan, and M. Grönholm, “Regulation of Integrin Activity and Signalling,” Biochimica Et Biophysica Acta 1790, no. 6 (2009): 431–444.

[141] L. Meng, H. Wu, J. Wu, et al., “Mechanisms of Immune Checkpoint Inhibitors: Insights Into the Regulation of Circular RNAs Involved in Cancer Hallmarks,” Cell Death & Disease 15, no. 1 (2024): 3.

[142] X. He and C. Xu, “Immune Checkpoint Signaling and Cancer Immunotherapy,” Cell Research 30, no. 8 (2020): 660–669.

[143] H. Dong, S. E. Strome, D. R. Salomao, et al., “Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion,” Nature Medicine 8, no. 8 (2002): 793–800.

[144] A. Ribas and J. D. Wolchok, “Cancer Immunotherapy Using Checkpoint Blockade,” Science 359, no. 6382 (2018): 1350–1355.

[145] P. Sharma, S. Goswami, D. Raychaudhuri, et al., “Immune Checkpoint Therapy-Current Perspectives and Future Directions,” Cell 186, no. 8 (2023): 1652–1669.

[146] I. Chau, “Pembrolizumab as a First-Line Treatment for Advanced Gastric Cancer,” The Lancet Oncology 24, no. 11 (2023): 1158–1159.

[147] J. Brahmer, K. L. Reckamp, P. Baas, et al., “Nivolumab Versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer,” New England Journal of Medicine 373, no. 2 (2015): 123–135.

[148] Y. Tie, H. Yang, R. Zhao, et al., “Safety and Efficacy of atezolizumab in the Treatment of Cancers: A Systematic Review and Pooled-analysis,” Drug Design, Development and Therapy 13 (2019): 523–538.

[149] L. A. Fecher, S. S. Agarwala, F. S. Hodi, and J. S. Weber, “Ipilimumab and Its Toxicities: A Multidisciplinary Approach,” The Oncologist 18, no. 6 (2013): 733–743.

[150] K. P. M. Suijkerbuijk, E. Kapiteijn, and R. J. Verheijden, “Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated with Checkpoint Inhibitors,” JAMA Oncology 6, no. 8 (2020): 1300–1301.

[151] M. A. Postow, R. Sidlow, and M. D. Hellmann, “Immune-Related Adverse Events Associated With Immune Checkpoint Blockade,” New England Journal of Medicine 378, no. 2 (2018): 158–168.

[152] J. R. Brahmer, C. Lacchetti, B. J. Schneider, et al., “Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline,” Journal of Clinical Oncology 36, no. 17 (2018): 1714–1768.

[153] D. Y. Wang, J. E. Salem, J. V. Cohen, et al., “Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis,” JAMA Oncology 4, no. 12 (2018): 1721–1728.

[154] C. Kreer, J. M. Kuepper, M. Zehner, et al., “N-Glycosylation Converts Non-Glycoproteins Into Mannose Receptor Ligands and Reveals Antigen-Specific T Cell Responses in Vivo,” Oncotarget 8, no. 4 (2017): 6857–6872.

[155] V. Jawa, F. Terry, J. Gokemeijer, et al., “T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-Clinical Assessment and Mitigation-Updated Consensus and Review,” Frontiers in Immunology 11 (2020): 1301.

[156] H. Schellekens, “Immunogenicity of Therapeutic Proteins: Clinical Implications and Future Prospects,” Clinical Therapeutics 24, no. 11 (2002): 1720–1740, discussion 1719.

[157] G. Wang, H. Wan, X. Jian, et al., “INeo-Epp: A Novel T-Cell HLA Class-I Immunogenicity or Neoantigenic Epitope Prediction Method Based on Sequence-Related Amino Acid Features,” BioMed Research International 2020 (2020): 5798356.

[158] P. J. Carter and V. Quarmby, “Immunogenicity Risk Assessment and Mitigation for Engineered Antibody and Protein Therapeutics,” Nature Reviews Drug Discovery 23, no. 12 (2024): 898–913.

[159] B. Reynisson, B. Alvarez, S. Paul, B. Peters, and M. Nielsen, “NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved Predictions of MHC Antigen Presentation by Concurrent Motif Deconvolution and Integration of MS MHC Eluted Ligand Data,” Nucleic Acids Research 48, no. W1 (2020): W449–W454.

[160] B. Chen, M. S. Khodadoust, N. Olsson, et al., “Predicting HLA Class II Antigen Presentation Through Integrated Deep Learning,” Nature Biotechnology 37, no. 11 (2019): 1332–1343.

[161] R. Vita, J. A. Overton, J. A. Greenbaum, et al., “The Immune Epitope Database (IEDB) 3.0,” Nucleic Acids Research 43, no. Database issue (2015): D405-12.

[162] A. S. Parker, Y. Choi, K. E. Griswold, and C. Bailey-Kellogg, “Structure-Guided Deimmunization of Therapeutic Proteins,” Journal of Computational Biology 20, no. 2 (2013): 152–165.

[163] H. C. Gasser, D. A. Oyarzún, J. A. Alfaro, and A. Rajan, “Tuning ProteinMPNN to Reduce Protein Visibility via MHC Class I Through Direct Preference Optimization,” Protein Engineering, Design & Selection: PEDS 38 (2025): gzaf003.

[164] H. C. Gasser, A. Rajan, and J. A. Alfaro, “A Novel Decoding Strategy for ProteinMPNN to Design With Less Visibility to Cytotoxic T-lymphocytes,” Computational and Structural Biotechnology Journal 27 (2025): 3693–3703.

[165] R. Mazor, J. A. Eberle, X. Hu, et al., “Recombinant Immunotoxin for Cancer Treatment With Low Immunogenicity by Identification and Silencing of Human T-cell Epitopes,” Proceedings of the National Academy of Sciences of the United States of America 111, no. 23 (2014): 8571–8576.

[166] W. Jankowski, J. McGill, H. A. D. Lagasse, et al., “Mitigation of T-Cell Dependent Immunogenicity by Reengineering Factor VIIa Analogue,” Blood Advances 3, no. 17 (2019): 2668–2678.

[167] C. E. Tinberg, S. D. Khare, J. Dou, et al., “Computational Design of Ligand-Binding Proteins With High Affinity and Selectivity,” Nature 501, no. 7466 (2013): 212–216.

[168] G. J. Rocklin, T. M. Chidyausiku, I. Goreshnik, et al., “Global Analysis of Protein Folding Using Massively Parallel Design, Synthesis, and Testing,” Science 357, no. 6347 (2017): 168–175.

[169] M. Mahmoudi, M. P. Landry, A. Moore, and R. Coreas, “The Protein Corona From Nanomedicine to Environmental Science,” Nature Reviews Materials 8 (2023): 422–438.

[170] F. M. Veronese and G. Pasut, “PEGylation, Successful Approach to Drug Delivery,” Drug Discovery Today 10, no. 21 (2005): 1451–1458.

[171] F. M. Veronese and G. Pasut, “PEGylation: Posttranslational Bioengineering of Protein Biotherapeutics,” Drug Discovery Today: Technologies 5, no. 2-3 (2008): e57–64.

[172] M. J. Roberts, M. D. Bentley, and J. M. Harris, “Chemistry for Peptide and Protein PEGylation,” Advanced Drug Delivery Reviews 54, no. 4 (2002): 459–476.

[173] S. Kamerkar, V. S. LeBleu, H. Sugimoto, et al., “Exosomes Facilitate Therapeutic Targeting of Oncogenic KRAS in Pancreatic Cancer,” Nature 546, no. 7659 (2017): 498–503.

[174] N. Yim, S. W. Ryu, K. Choi, et al., “Exosome Engineering for Efficient Intracellular Delivery of Soluble Proteins Using Optically Reversible Protein-Protein Interaction Module,” Nature Communications 7 (2016): 12277.

[175] U. Sterzenbach, U. Putz, L. H. Low, J. Silke, S. S. Tan, and J. Howitt, “Engineered Exosomes as Vehicles for Biologically Active Proteins,” Molecular Therapy 25, no. 6 (2017): 1269–1278.

[176] F. Danhier, O. Feron, and V. Preat, “To Exploit the Tumor Microenvironment: Passive and Active Tumor Targeting of Nanocarriers for Anti-Cancer Drug Delivery,” Journal of Controlled Release 148, no. 2 (2010): 135–146.

[177] A. Perucca, A. G. Llonin, O. M. Benach, et al., “Micro Immune Response On-Chip (MIRO) Models the Tumour-Stroma Interface for Immunotherapy Testing,” Nature Communications 16, no. 1 (2025): 1279.

[178] W. M. Pardridge, “Drug Transport Across the Blood-Brain Barrier,” Journal of Cerebral Blood Flow and Metabolism 32, no. 11 (2012): 1959–1972.

[179] D. D. Sahtoe, A. Coscia, N. Mustafaoglu, et al., “Transferrin Receptor Targeting by De Novo Sheet Extension,” PNAS 118, no. 17 (2021).

[180] Y. Li, B. S. Harris, Z. Li, et al., “Water, Solute, and Ion Transport in De Novo-Designed Membrane Protein Channels,” ACS Nano 19, no. 2 (2025): 2185–2195.

[181] A. Neesse, C. A. Bauer, D. Ohlund, et al., “Stromal Biology and Therapy in Pancreatic Cancer: Ready for Clinical Translation?,” Gut 68, no. 1 (2019): 159–171.

[182] J. L. Chitty and T. R. Cox, “The Extracellular Matrix in Cancer: From Understanding to Targeting,” Trends in Cancer 11, no. 9 (2025): 839–849.

[183] S. J. Lunt, A. Fyles, R. P. Hill, and M. Milosevic, “Interstitial Fluid Pressure in Tumors: Therapeutic Barrier and Biomarker of Angiogenesis,” Future Oncology 4, no. 6 (2008): 793–802.

[184] B. Diener, L. Carrick Jr, and R. S. Berk, “In Vivo Studies With Collagenase From Pseudomonas aeruginosa,” Infection and Immunity 7, no. 2 (1973): 212–217.

[185] L. Eikenes, O. S. Bruland, C. Brekken, and L. Davies Cde, “Collagenase Increases the Transcapillary Pressure Gradient and Improves the Uptake and Distribution of Monoclonal Antibodies in human Osteosarcoma Xenografts,” Cancer Research 64, no. 14 (2004): 4768–4773.

[186] M. Kato, Y. Hattori, M. Kubo, and Y. Maitani, “Collagenase-1 Injection Improved Tumor Distribution and Gene Expression of Cationic Lipoplex,” International Journal of Pharmaceutics 423, no. 2 (2012): 428–434.

[187] M. Braun, A. Tripp, M. Chakatok, et al., “Computational Enzyme Design by Catalytic Motif Scaffolding,” Nature 649, no. 8095 (2026): 237–245.

[188] J. B. Siegel, A. Zanghellini, H. M. Lovick, et al., “Computational Design of an Enzyme Catalyst for a Stereoselective Bimolecular Diels-Alder Reaction,” Science 329, no. 5989 (2010): 309–313.

[189] T. Hayes, R. Rao, H. Akin, et al., “Simulating 500 Million Years of Evolution With a Language Model,” Science 387, no. 6736 (2025): 850–858.

[190] R. Wisniewski, “Principles of the Design and Operational Considerations of Large Scale High Performance Liquid Chromatography (HPLC) Systems for Proteins and Peptides Purification,” Bioseparation 3, no. 2-3 (1992): 77–143.

[191] J. Dou, A. A. Vorobieva, W. Sheffler, et al., “De Novo Design of a Fluorescence-Activating Beta-Barrel,” Nature 561, no. 7724 (2018): 485–491. Created a functional fluorescent beta-barrel from scratch, showcasing precise computational control over protein folding and function.

[192] C. R. Freschlin, K. K. Yang, and P. A. Romero, “Scalable and Cost-Efficient Custom Gene Library Assembly From Oligopools,” Science Advances 12, no. 21 (2026): eady2279.

[193] L. Zhang, “Multi-epitope Vaccines: A Promising Strategy Against Tumors and Viral Infections,” Cellular & Molecular Immunology 15, no. 2 (2018): 182–184.

[194] P. A. Ott, Z. Hu, D. B. Keskin, et al., “An Immunogenic Personal Neoantigen Vaccine for Patients With Melanoma,” Nature 547, no. 7662 (2017): 217–221.

[195] U. Sahin, P. Oehm, E. Derhovanessian, et al., “An RNA Vaccine Drives Immunity in Checkpoint-Inhibitor-Treated Melanoma,” Nature 585, no. 7823 (2020): 107–112.

[196] C. L. Trimble, M. P. Morrow, K. A. Kraynyak, et al., “Safety, Efficacy, and Immunogenicity of VGX-3100, a Therapeutic Synthetic DNA Vaccine Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins for Cervical Intraepithelial Neoplasia 2/3: A Randomised, Double-blind, Placebo-Controlled Phase 2b Trial,” Lancet 386, no. 10008 (2015): 2078–2088.

[197] P. W. Kantoff, C. S. Higano, N. D. Shore, et al., “Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer,” New England Journal of Medicine 363, no. 5 (2010): 411–422.

[198] C. J. Melief and S. H. van der Burg, “Immunotherapy of Established (pre)Malignant Disease by Synthetic Long Peptide Vaccines,” Nature Reviews Cancer 8, no. 5 (2008): 351–360.

[199] Y. Ruan, S. Chao, X. Hu, et al., “FN3 Domain Displaying Double Epitopes: A Cost-Effective Strategy for Producing Substitute Antigens,” Frontiers in Molecular Biosciences 8 (2021): 742617.

[200] T. M. Caradonna and A. G. Schmidt, “Protein Engineering Strategies for Rational Immunogen Design,” NPJ Vaccines 6, no. 1 (2021): 154.

[201] B. E. Correia, J. T. Bates, R. J. Loomis, et al., “Proof of Principle for Epitope-Focused Vaccine Design,” Nature 507, no. 7491 (2014): 201–206. Pioneered structure-based epitope-focused vaccine design, demonstrating computational precision can guide immune targeting.

[202] J. Marcandalli, B. Fiala, S. Ols, et al., “Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus,” Cell 176, no. 6 (2019): 1420–1431.

[203] A. Chevalier, D. A. Silva, G. J. Rocklin, et al., “Massively Parallel De Novo Protein Design for Targeted Therapeutics,” Nature 550, no. 7674 (2017): 74–79.

[204] X. Chen, J. L. Zaro, and W. C. Shen, “Fusion Protein Linkers: Property, Design and Functionality,” Advanced Drug Delivery Reviews 65, no. 10 (2013): 1357–1369.

[205] J. B. Bale, S. Gonen, Y. Liu, et al., “Accurate Design of Megadalton-Scale Two-Component Icosahedral Protein Complexes,” Science 353, no. 6297 (2016): 389–394.

[206] A. C. Walls, B. Fiala, A. Schafer, et al., “Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2,” Cell 183, no. 5 (2020): 1367–1382.

[207] J. Y. Song, W. S. Choi, J. Y. Heo, et al., “Safety and Immunogenicity of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) Adjuvanted With AS03: A Randomised, Placebo-Controlled, Observer-Blinded Phase 1/2 Trial,” EClinicalMedicine 51 (2022): 101569.

[208] J. Y. Song, W. S. Choi, J. Y. Heo, et al., “Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine GBP510 Adjuvanted With AS03: Interim Results of a Randomised, Active-Controlled, Observer-Blinded, Phase 3 Trial,” EClinicalMedicine 64 (2023): 102140.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.